Your browser is no longer supported. Please, upgrade your browser.
Aethlon Medical, Inc.
Index- P/E- EPS (ttm)-0.79 Insider Own0.80% Shs Outstand12.07M Perf Week3.85%
Market Cap33.70M Forward P/E- EPS next Y-0.63 Insider Trans-21.19% Shs Float11.78M Perf Month30.43%
Income-5.80M PEG- EPS next Q-0.17 Inst Own10.40% Short Float4.89% Perf Quarter74.19%
Sales0.60M P/S56.16 EPS this Y63.60% Inst Trans- Short Ratio0.29 Perf Half Y26.17%
Book/sh1.14 P/B2.37 EPS next Y-3.30% ROA-49.70% Target Price- Perf Year134.78%
Cash/sh1.16 P/C2.32 EPS next 5Y- ROE-54.60% 52W Range1.18 - 4.34 Perf YTD9.31%
Dividend- P/FCF- EPS past 5Y36.60% ROI-67.80% 52W High-37.79% Beta0.66
Dividend %- Quick Ratio9.90 Sales past 5Y-3.10% Gross Margin- 52W Low128.81% ATR0.22
Employees8 Current Ratio9.90 Sales Q/Q- Oper. Margin- RSI (14)62.95 Volatility5.56% 8.51%
OptionableNo Debt/Eq0.00 EPS Q/Q88.70% Profit Margin- Rel Volume0.30 Prev Close2.67
ShortableYes LT Debt/Eq0.00 EarningsOct 28 AMC Payout- Avg Volume1.99M Price2.70
Recom2.00 SMA2010.54% SMA5035.83% SMA20059.85% Volume589,200 Change1.12%
Jan-06-21 08:02AM  
Jan-04-21 08:02AM  
Dec-16-20 08:02AM  
Nov-03-20 08:01AM  
Oct-29-20 11:45AM  
Oct-28-20 04:15PM  
Oct-19-20 08:01AM  
Oct-13-20 10:30AM  
Sep-09-20 08:01AM  
Aug-27-20 08:01AM  
Aug-11-20 04:15PM  
Aug-06-20 12:43AM  
Jun-25-20 04:15PM  
Jun-22-20 08:31AM  
Jun-18-20 12:49PM  
Jun-16-20 08:30AM  
Mar-24-20 08:58AM  
Mar-06-20 12:08PM  
Feb-25-20 03:25PM  
Feb-24-20 10:22AM  
Feb-17-20 01:37PM  
Feb-13-20 05:35AM  
Feb-10-20 04:15PM  
Feb-06-20 08:01AM  
Jan-23-20 01:02PM  
Jan-22-20 02:28PM  
Jan-21-20 02:40PM  
Jan-17-20 08:49AM  
Dec-17-19 04:18PM  
Dec-13-19 07:00AM  
Nov-15-19 05:04AM  
Nov-01-19 04:15PM  
Oct-29-19 03:17PM  
Oct-28-19 07:00AM  
Oct-14-19 03:55PM  
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shah ChetanDirectorDec 17Sale2.1126,85256,58016,641Dec 18 05:00 PM